Effects of febuxostat on insulin resistance and inflammatory factors in patients with type 2 diabetes mellitus combined with hyperuricemia
Objective To investigated the effects of febuxostat on insulin resistance and inflammatory factors in patients with type 2 diabetes mellitus(T2DM)combined with asymptomatic hyperuricemia(HUA),observed the clinical efficacy and its safety.Methods Ninety-one patients with T2DM combined with HUA who attended the outpatient clinic of the Department of Endocrinology of the Bishan Hospital of Chongqing Medical University from December 2021 to December 2022 were selected,and the patients were divided into experimental and control groups according to the random number table method,with 47 cases in the experimental group and 44 cases in the control group.The control group was treated with hypoglycemic drugs and insulin on the basis of conventional drug therapy,and the experimental group was treated with febuxostat on the basis of the control group,and the levels of serum uric acid(UA),homeostasis model assessment-IR(HOMA-IR),hypersensitive C-reactive protein(hs-CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)in the experimental and control groups were compared after treatment and drug safety.Results Fasting blood glucose,fasting insulin,HOMA-IR,glycosylated hemoglobin,UA,creatinine,blood urea nitrogen,total cholesterol,triglyceride,low-density lipoprotein-C,hs-CRP,IL-6,TNF-α levels were lower in the experimental group than those in the control group after treatment with febuxostat intervention;the differences were statistically significant(t=-4.111,-4.185,-6.550,-2.725,-2.725,-6.980,-3.994,-2.737,-2.150,-3.098,-3.500,-2.328,-5.441,-2.381;all P<0.05),and glomerular filtration rate and high-density lipoprotein-C levels were higher than those in the control group,and the differences were statistically significant(t=-4.013,-2.376;all P<0.05).Conclusion Febuxostat intervention therapy could effectively reduce uric acid levels,improve insulin resistance and reduce the inflammatory response in patients with T2DM combined with HUA.
NETL
NSTL
万方数据
